Tag: drug development
-

Cerevance Solengepras Meets Phase 3 Endpoint in Parkinson’s Disease
Cerevance’s GPR6 inverse agonist solengepras reduced daily OFF time by 0.61 hours versus placebo in the Phase 3 ARISE trial.
-

Sanofi’s Pipeline Reset Signals a New Era of R&D Discipline
Sanofi’s latest pipeline review highlights a shift from expanding R&D portfolios to making more disciplined investment decisions. Here’s why that matters for the future of big pharma.
-

AstraZeneca Keeps Its $80 Billion Goal Despite a Major Trial Setback
AstraZeneca reaffirmed its $80 billion revenue ambition after reporting solid second-quarter results. Strong oncology and rare disease sales helped restore confidence following the failure of a major Wainua trial.
-

Why AstraZeneca Says Drug Development Must Move at “Chinese Speed”
AstraZeneca believes the next pharmaceutical race will be defined not only by scientific innovation, but also by development speed. As competition from Chinese biotech grows, AI could help accelerate drug development and improve efficiency.
-

Why Big Pharma Is Buying Biotech Again: The Patent Cliff Explained
Patent expirations are reshaping the pharmaceutical industry. Here’s why Big Pharma is buying biotech companies again—and what investors should watch next.
-

Can GSK Deliver Its £40 Billion Growth Ambition?
GlaxoSmithKline (GSK) will unveil its long-term growth strategy on July 28. As CEO Luke Miels leads his first major investor event, the focus will be on whether oncology expansion and HIV transformation can realistically support the company’s £40 billion revenue ambition by 2031.
